OLMA Olema Oncology, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1750284 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-57.3%
TTM EPS YoY-36.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-69.8%
ROA-59.5%
ROIC (approx.)-67.3%
Asset turnover—
Leverage & solvency
Liabilities / assets16.4%
Debt / equity0.00x
Current ratio6.12x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.75x
Accruals ratio-14.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $67.60M | $57.78M | $49.23M | $43.22M | $39.95M | $43.90M | $30.62M | $32.30M |
| SG&A expense | $9.93M | $9.39M | $8.75M | $6.86M | $5.93M | $3.96M | $4.25M | $4.47M |
| Operating income | -$77.53M | -$67.18M | -$57.99M | -$50.08M | -$45.88M | -$47.86M | -$34.87M | -$36.77M |
| Net income | -$73.60M | -$63.20M | -$53.09M | -$46.06M | -$42.22M | -$43.78M | -$30.39M | -$33.57M |
| EBITDA | -$77.43M | -$67.08M | -$57.87M | -$49.90M | -$45.83M | -$47.73M | -$34.74M | -$36.65M |
| EPS (basic) | -0.73 | -0.61 | -0.52 | — | -0.49 | -0.51 | -0.36 | — |
| EPS (diluted) | -0.73 | -0.61 | -0.52 | — | -0.49 | -0.51 | -0.36 | — |
| Weighted avg. shares (diluted) | 101.09M | 104.45M | 102.80M | — | 85.73M | 85.50M | 85.43M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $47.52M | $48.60M | $52.55M | $48.30M | $35.26M | $52.47M | $50.64M | $139.48M |
| Short-term investments | $366.25M | $412.47M | $452.80M | $457.14M | $293.70M | $309.44M | $342.07M | $294.61M |
| Current assets | $423.43M | $469.88M | $513.23M | $515.45M | $334.33M | $367.73M | $396.66M | $438.47M |
| PP&E, net | $1.65M | $382,000 | $356,000 | $274,000 | $486,000 | $560,000 | $653,000 | $746,000 |
| Total assets | $441.07M | $486.58M | $530.64M | $533.43M | $352.45M | $382.00M | $409.64M | $450.98M |
| Current liabilities | $69.23M | $53.01M | $47.17M | $51.80M | $41.66M | $33.16M | $26.06M | $41.76M |
| Total liabilities | $72.23M | $56.01M | $50.17M | $54.87M | $44.97M | $36.77M | $26.19M | $42.02M |
| Shareholders' equity | $368.84M | $430.56M | $480.48M | $478.56M | $307.49M | $345.24M | $383.45M | $408.96M |
| Shares outstanding | 87.54M | 87.45M | 87.33M | 81.38M | 68.65M | 68.63M | 68.33M | 74.31M |
| Cash flow statement | ||||||||
| Operating cash flow | -$47.11M | -$45.90M | -$45.99M | -$38.33M | -$34.53M | -$29.88M | -$43.98M | -$26.28M |
| Capital expenditure | $900,000 | — | — | — | $0 | — | — | $0 |
| Free cash flow | -$48.01M | — | — | — | -$34.53M | — | — | -$26.28M |
| Investing cash flow | $45.60M | $40.84M | $4.53M | -$162.18M | $17.27M | $34.23M | -$45.08M | -$114.42M |
| Financing cash flow | $434,000 | $1.11M | $45.70M | $213.55M | $41,000 | -$2.52M | $222,000 | $244.30M |
| Depreciation & amortization | $94,000 | $102,000 | $119,000 | $187,000 | $43,000 | $132,000 | $128,000 | $116,000 |
| Stock-based compensation | $12.08M | $12.90M | $10.15M | $4.27M | $4.25M | $4.69M | $4.38M | $6.32M |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.